TY - JOUR
T1 - Central Nervous System Involvement in Peripheral T Cell Lymphoma
AU - Chihara, Dai
AU - Oki, Yasuhiro
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Purpose of Review: Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease. Recent Findings: Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2–6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement CloseSPigtSPi 1 has been consistently found to be a risk factor for CNS relapse. Summary: Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.
AB - Purpose of Review: Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease. Recent Findings: Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2–6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement CloseSPigtSPi 1 has been consistently found to be a risk factor for CNS relapse. Summary: Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.
KW - Central nervous system
KW - Peripheral T cell lymphoma
KW - Relapse
KW - Review
UR - http://www.scopus.com/inward/record.url?scp=85041104912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041104912&partnerID=8YFLogxK
U2 - 10.1007/s11899-018-0431-4
DO - 10.1007/s11899-018-0431-4
M3 - Review article
C2 - 29374824
AN - SCOPUS:85041104912
SN - 1558-8211
VL - 13
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 1
ER -